FF
CRSP icon

Farrow Financial’s CRISPR Therapeutics CRSP Stock Holding History

Farrow Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
19,643
+2,664
+16% +$140K 0.57% 39
2026
Q1 		$808K Buy
16,979
+849
+5% +$44.8K 0.46% 42
2025
Q4 		$846K Sell
16,130
-570
-3% -$34.1K 0.49% 41
2025
Q3 		$1.08M Sell
16,700
-512
-3% -$29.4K 0.63% 38
2025
Q2 		$837K Sell
17,212
-144
-0.8% -$5.57K 0.51% 40
2025
Q1 		$591K Sell
17,356
-2,741
-14% -$116K 0.4% 42
2024
Q4 		$777K Buy
20,097
+270
+1% +$12.7K 0.5% 40
2024
Q3 		$931K Buy
19,827
+2,467
+14% +$125K 0.59% 39
2024
Q2 		$938K Buy
17,360
+341
+2% +$19.7K 0.64% 39
2024
Q1 		$1.16M Sell
17,019
-1,901
-10% -$136K 0.81% 41
2023
Q4 		$1.18M Buy
+18,920
New +$1.05M 0.89% 38

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Farrow Financial's CRSP Position: Q2 2026 in Review

Farrow Financial increased its CRISPR Therapeutics (CRSP) stake by 16% in Q2 2026, buying an estimated $140K and bringing the position to 19,643 shares worth $1.07M. The position accounts for 0.57% of the portfolio, ranked #39.

Farrow Financial first reported a position in CRSP in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.18M in Q4 2023. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Farrow Financial held 19,643 shares of CRISPR Therapeutics worth $1.07M as of Q2 2026.
  • Farrow Financial bought 2,664 CRISPR Therapeutics shares in Q2 2026, an estimated $140K.
  • CRISPR Therapeutics made up 0.57% of Farrow Financial's portfolio in Q2 2026, its #39 holding.
  • Farrow Financial first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Farrow Financial's CRISPR Therapeutics position peaked at $1.18M in Q4 2023.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Farrow Financial's 13F filing for Q2 2026, filed 4 Aug 2026.